Skip to main content

Tailored cell-based therapies for frontotemporal dementia and related genetically defined CNS orphan indications

Project description

In situ drug delivery to the brain for CNS diseases

Neurodegenerative disorders affect millions of individuals worldwide and also have a tremendous impact on their families. Treatments are limited due to the inability of therapeutics to cross the blood–brain barrier and reach the causative cell population in the brain. To address this problem, the EU-funded iProg project is developing a clinically validated platform that can deliver drugs locally within the brain with minimal systemic exposure. Using this device, researchers will prepare for a clinical trial to deliver a novel neurotrophic therapy against frontotemporal degeneration, a type of dementia caused by mutations in the progranulin gene. Results will have important implications for the treatment of neurodegenerative disorders.

Call for proposal


See other projects for this call

Sub call



Net EU contribution
€ 50 000,00
Halsovagen 7, Novum
141 57 Huddinge

See on map

Östra Sverige Stockholm Stockholms län
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
Other funding
€ 50 000,00